Quest Laboratories Ltd

Quest Laboratories Other Announcement

Quest Laboratories reported no deviation in IPO fund utilisation for the half year ended September 2026. Its statement was reviewed by the Audit Committee.

Quest Laboratories H1 FY27 Results: Net Profit ₹9 Cr, Up 11.1% YoY

Quest Laboratories approved unaudited standalone half-year results for the period ended September 30, 2026, with a full results statement attached. Revenue, profit and balance sheet figures are disclosed in the enclosed statements.

Key figure

Net profit ₹9 Cr · +11.1% YoY

Quest Laboratories Annual General Meeting

Quest Laboratories Limited held its 28th Annual General Meeting on September 30, 2026. The company discussed and placed standard business resolutions for shareholder consideration and approval.

Quest Laboratories Partnership

Quest Laboratories Limited entered a strategic advisory collaboration with Niraga Capitals Private Limited to support its growth, corporate development, and strategic initiatives.

Quest Laboratories Business Update

Quest Laboratories updated its third-quarter business position, reporting export orders of ₹10.71 Crore and domestic sales of ₹16.90 Crore, with a total order book of ₹39.73 Crore.

Order book

₹39.73 Cr

Quest Laboratories Capacity Expansion

Quest Laboratories Limited completed its Phase-I manufacturing expansion, with a new 12,000 sq. ft. facility becoming operational in September 2026.

building expansion area

12000.0 sq. ft.

Quest Laboratories Annual General Meeting

Quest Laboratories Limited has scheduled its 28th Annual General Meeting for September 30, 2026, to transact agenda items including financial statements and director appointments.